Trading results for 10 June 2025
Tuesday was surprisingly as calm as Monday. The reason was the ongoing U.S.-China trade negotiations in London which, on the one hand, appear to be progressing well, but on the other – remain unresolved. As a result, uncertainty continues to hang in the air. Investors are holding their breath, wary of disrupting a potential breakthrough: what if the two sides really do reach a meaningful agreement? As a result, the market showed a slight positive bias, but only in very modest doses.
The trading results were therefore quite predictable – all major U.S. indexes posted gains, though none were significant, each merely taking another small step upwards. The biggest increase came from the tech-heavy NASDAQ Composite, which rose by 0.63%. The broad-market S&P 500 was close behind with a gain of 0.55%. The most modest rise, as usual, was seen in the blue-chip Dow Jones (DJIA-30), which closed up by 0.25% compared to Monday.
Sectoral analysis also painted a relatively positive picture, suggesting that moderate optimism is spreading across the market. Nine out of eleven economic sectors ended the day in the green. Only industrial and financial stocks posted losses, declining by 0.34% and 0.11% on average, respectively.
Investors were also cheered by the performance of the ITS index family. The ITS World Index (ITSW), which tracks global companies, hit another all-time high for the third consecutive day, climbing by 0.35%. Even stronger was the performance of the ITS Shariah Index (ITSS), focused on Shariah-compliant securities, which rose by nearly a full percentage point (+0.95%). Leading gains in both indexes were shares in Tesla (TSLA, +5.67%) and pharmaceutical giant Eli Lilly (LLY, +4.33%).
Tesla appears to be gradually recovering from the aftermath of the recent spat between Donald Trump and Elon Musk and is attempting to return to pre-conflict levels. Eli Lilly’s sharp rise, meanwhile, followed news that the company had introduced new terms of engagement with telemedicine platforms Ro and LifeMD (LFMD), ensuring that compounded versions of its GLP-1 weight-loss drugs would no longer be sold on those websites. According to analysts, this should boost Eli Lilly’s profits, as telemedicine had previously “eaten” into part of its revenue. Unsurprisingly, investors reacted positively, and the stock saw strong buying activity.
Overall, in the absence of major news, market conditions remain calm. However, investors should keep in mind that consumer inflation data is due out on Wednesday – a release that markets traditionally react to with heightened sensitivity. Moreover, the London talks are also expected to conclude soon. Investors will be closely watching how events unfold, and it is quite possible that Wednesday’s calm may give way to a storm.